View ValuationHanda Pharmaceuticals 향후 성장Future 기준 점검 1/6Handa Pharmaceuticals 의 수익은 연간 3.4% 감소할 것으로 예상되는 반면, 연간 수익은 6.9% 로 증가할 것으로 예상됩니다. EPS는 연간 4.3% 만큼 성장할 것으로 예상됩니다.핵심 정보6.9%이익 성장률4.25%EPS 성장률Pharmaceuticals 이익 성장16.2%매출 성장률-3.4%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트28 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesDeclared Dividend • Jun 19Dividend increased to NT$2.07Dividend of NT$2.07 is 38% higher than last year. Ex-date: 6th July 2026 Payment date: 30th July 2026 Dividend yield will be 2.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (41% earnings payout ratio) but not covered by cash flows (103% cash payout ratio). The dividend has increased by an average of 41% per year over the past 2 years and payments have been stable during that time. Earnings per share has grown by 53% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 20%After last week's 20% share price gain to NT$81.80, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 18x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 49% over the past three years.Reported Earnings • May 20First quarter 2026 earnings released: EPS: NT$0.46 (vs NT$0.31 in 1Q 2025)First quarter 2026 results: EPS: NT$0.46 (up from NT$0.31 in 1Q 2025). Revenue: NT$209.6m (up 16% from 1Q 2025). Net income: NT$76.2m (up 69% from 1Q 2025). Profit margin: 36% (up from 25% in 1Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 01Full year 2025 earnings released: EPS: NT$4.85 (vs NT$3.37 in FY 2024)Full year 2025 results: EPS: NT$4.85 (up from NT$3.37 in FY 2024). Revenue: NT$1.73b (up 108% from FY 2024). Net income: NT$749.8m (up 59% from FY 2024). Profit margin: 43% (down from 57% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.공시 • Mar 13Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2026Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2026. Location: 2 floor no,12, chou tzu st., neihu district, taipei city TaiwanNew Risk • Jan 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 135% Dividend yield: 1.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Dividend is not well covered by cash flows (135% cash payout ratio). Share price has been volatile over the past 3 months (7.4% average weekly change).Valuation Update With 7 Day Price Move • Dec 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$87.60, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 26% over the past three years.Valuation Update With 7 Day Price Move • Dec 10Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$100.00, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 8.5% over the past three years.Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: NT$1.34 (vs NT$1.05 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.34 (up from NT$1.05 in 3Q 2024). Revenue: NT$489.5m (up 134% from 3Q 2024). Net income: NT$209.5m (up 43% from 3Q 2024). Profit margin: 43% (down from 70% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.공시 • Nov 05Handa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of TWD 1.232 billion.Handa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of TWD 1.232 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 11,200,000 Price(maximum): TWD 110Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$139, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 153% over the past three years.New Risk • Sep 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (44% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change).Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 29%After last week's 29% share price gain to NT$106, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 94% over the past three years.New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 44% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.Upcoming Dividend • Jun 25Upcoming dividend of NT$1.51 per shareEligible shareholders must have bought the stock before 02 July 2025. Payment date: 25 July 2025. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.6%).Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to NT$60.20, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 18x in the Pharmaceuticals industry in Taiwan. Negligible returns to shareholders over past three years.New Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Profit margins are more than 30% lower than last year (46% net profit margin).공시 • Feb 20Handa Pharmaceuticals, Inc. announced that it expects to receive TWD 1.156 billion in funding from ScinoPharm Taiwan, Ltd.Handa Pharmaceuticals, Inc. announced a private placement of 17,000,000 shares at a price of TWD 68 per share for the gross proceeds of TWD 1,156,000,000 on February 18, 2025. The transaction will include participation from ScinoPharm Taiwan, Ltd. The transaction has been approved by investor's boards of directors.공시 • Feb 19Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2025Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2025. Location: 2 floor no,1, sec.3 chung hsiao e. rd., da-an district, taipei city TaiwanValuation Update With 7 Day Price Move • Dec 23Investor sentiment improves as stock rises 19%After last week's 19% share price gain to NT$60.60, the stock trades at a trailing P/E ratio of 18.9x. Average forward P/E is 12x in the Pharmaceuticals industry in Taiwan. Negligible returns to shareholders over past three years.New Risk • Dec 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Profit margins are more than 30% lower than last year (46% net profit margin).New Risk • Oct 25New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Continuous dividend paying years: 1 Dividend yield: 1.7% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (8.6% average weekly change). Profit margins are more than 30% lower than last year (46% net profit margin).Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.73 (vs NT$1.90 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.73 (down from NT$1.90 in 2Q 2023). Revenue: NT$215.5m (down 24% from 2Q 2023). Net income: NT$102.4m (down 59% from 2Q 2023). Profit margin: 48% (down from 87% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$82.30, the stock trades at a trailing P/E ratio of 19.4x. Average forward P/E is 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 187% over the past three years.Valuation Update With 7 Day Price Move • May 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$109, the stock trades at a trailing P/E ratio of 25.6x. Average forward P/E is 13x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 317% over the past three years.Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.83 (vs NT$1.90 in 1Q 2023)First quarter 2024 results: EPS: NT$0.83 (down from NT$1.90 in 1Q 2023). Revenue: NT$217.4m (down 23% from 1Q 2023). Net income: NT$117.1m (down 53% from 1Q 2023). Profit margin: 54% (down from 87% in 1Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$141, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 465% over the past three years.New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (8.4% increase in shares outstanding).Valuation Update With 7 Day Price Move • Apr 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$144, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 415% over the past three years.공시 • Apr 03Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024.Reported Earnings • Apr 03Full year 2023 earnings released: EPS: NT$5.41 (vs NT$0.32 loss in FY 2022)Full year 2023 results: EPS: NT$5.41 (up from NT$0.32 loss in FY 2022). Revenue: NT$1.11b (up 460% from FY 2022). Net income: NT$726.9m (up NT$766.9m from FY 2022). Profit margin: 66% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 79% per year, which means it is significantly lagging earnings growth.New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (79% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (8.4% increase in shares outstanding).Reported Earnings • Dec 28Third quarter 2023 earnings released: EPS: NT$1.07 (vs NT$0.18 in 3Q 2022)Third quarter 2023 results: EPS: NT$1.07 (up from NT$0.18 in 3Q 2022). Revenue: NT$240.0m (up 206% from 3Q 2022). Net income: NT$146.0m (up NT$122.8m from 3Q 2022). Profit margin: 61% (up from 30% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 70% p.a. on average during the next 2 years, compared to a 29% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 99% per year whereas the company’s share price has increased by 98% per year.New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (120% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (8.3% increase in shares outstanding).New Risk • Sep 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (120% accrual ratio). Minor Risk Shareholders have been diluted in the past year (7.9% increase in shares outstanding).Reported Earnings • Apr 22Full year 2022 earnings released: NT$0.32 loss per share (vs NT$2.10 loss in FY 2021)Full year 2022 results: NT$0.32 loss per share (improved from NT$2.10 loss in FY 2021). Revenue: NT$197.7m (up NT$168.4m from FY 2021). Net loss: NT$40.0m (loss narrowed 84% from FY 2021). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 17First half 2022 earnings released: NT$0.71 loss per share (vs NT$1.01 loss in 1H 2021)First half 2022 results: NT$0.71 loss per share (up from NT$1.01 loss in 1H 2021). Revenue: NT$41.0m (up 198% from 1H 2021). Net loss: NT$86.4m (loss narrowed 26% from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.Reported Earnings • Apr 30Full year 2021 earnings released: NT$2.10 loss per share (vs NT$2.44 loss in FY 2020)Full year 2021 results: NT$2.10 loss per share (up from NT$2.44 loss in FY 2020). Net loss: NT$247.7m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 18First half 2021 earnings released: NT$1.01 loss per share (vs NT$1.26 loss in 1H 2020)First half 2021 results: Net loss: NT$116.6m (loss narrowed 20% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.공시 • Mar 20Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2021Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2021.Is New 90 Day High Low • Feb 25New 90-day high: NT$30.70The company is up 15% from its price of NT$26.80 on 27 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period.분석 기사 • Feb 24Handa Pharmaceuticals'(GTSM:6620) Share Price Is Down 26% Over The Past Three Years.Handa Pharmaceuticals, Inc. ( GTSM:6620 ) shareholders should be happy to see the share price up 12% in the last month...Is New 90 Day High Low • Jan 04New 90-day high: NT$28.15The company is up 35% from its price of NT$20.90 on 07 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 12% over the same period.분석 기사 • Dec 29We Think Handa Pharmaceuticals (GTSM:6620) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Is New 90 Day High Low • Nov 07New 90-day high: NT$27.15The company is up 1.0% from its price of NT$26.85 on 07 August 2020. The Taiwanese market is also up 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: NT$22.05The company is down 24% from its price of NT$29.15 on 23 June 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.이익 및 매출 성장 예측TPEX:6620 - 애널리스트 향후 추정치 및 과거 재무 데이터 (TWD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20271,629854939963112/31/20261,31262086690313/31/20261,758781323359N/A12/31/20251,729750227244N/A9/30/20251,617683175194N/A6/30/20251,338621236252N/A3/31/2025794401289297N/A12/31/2024831473490498N/A9/30/2024943453571576N/A6/30/2024973452745747N/A3/31/2024992597917917N/A12/31/20231,106727667668N/A9/30/2023956707394394N/A6/30/20237235407980N/A3/31/2023508250-124-123N/A12/31/2022198-40-212-212N/A9/30/202256-173-162-160N/A6/30/202256-217-135-134N/A3/31/202243-233-161-157N/A12/31/202129-248-186-179N/A9/30/202129-250-242-233N/A6/30/202129-253-298-286N/A3/31/202129-268-307-297N/A12/31/202029-282-316-308N/A9/30/202034-273-276-271N/A6/30/202038-263-237-234N/A3/31/202061-220-236-235N/A12/31/201984-178N/A-235N/A9/30/201993-160N/A-236N/A6/30/2019103-141N/A-237N/A3/31/201998-154N/A-207N/A12/31/201894-167N/A-177N/A9/30/201881-167N/A-148N/A6/30/201869-167N/A-118N/A3/31/201830363N/A173N/A12/31/2017538293N/A464N/A9/30/2017620368N/A465N/A6/30/2017702442N/A467N/A3/31/2017457235N/A167N/A12/31/201621129N/A-133N/A9/30/2016119-43N/A-138N/A6/30/201628-115N/A-143N/A3/31/201614-121N/A-126N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 6620 의 연간 예상 수익 증가율(6.9%)이 saving rate(1.3%)보다 높습니다.수익 vs 시장: 6620 의 연간 수익(6.9%)이 TW 시장(27.2%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 6620 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 6620 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -3.4%).고성장 매출: 6620 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -3.4%).주당순이익 성장 예측향후 자기자본이익률미래 ROE: 6620의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/03 21:21종가2026/07/03 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Handa Pharmaceuticals, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullKGI Securities Co. Ltd.Hsuan ChenKGI Securities Co. Ltd.Xin Ying JiangYuanta Research
Declared Dividend • Jun 19Dividend increased to NT$2.07Dividend of NT$2.07 is 38% higher than last year. Ex-date: 6th July 2026 Payment date: 30th July 2026 Dividend yield will be 2.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (41% earnings payout ratio) but not covered by cash flows (103% cash payout ratio). The dividend has increased by an average of 41% per year over the past 2 years and payments have been stable during that time. Earnings per share has grown by 53% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 20%After last week's 20% share price gain to NT$81.80, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 18x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 49% over the past three years.
Reported Earnings • May 20First quarter 2026 earnings released: EPS: NT$0.46 (vs NT$0.31 in 1Q 2025)First quarter 2026 results: EPS: NT$0.46 (up from NT$0.31 in 1Q 2025). Revenue: NT$209.6m (up 16% from 1Q 2025). Net income: NT$76.2m (up 69% from 1Q 2025). Profit margin: 36% (up from 25% in 1Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 01Full year 2025 earnings released: EPS: NT$4.85 (vs NT$3.37 in FY 2024)Full year 2025 results: EPS: NT$4.85 (up from NT$3.37 in FY 2024). Revenue: NT$1.73b (up 108% from FY 2024). Net income: NT$749.8m (up 59% from FY 2024). Profit margin: 43% (down from 57% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
공시 • Mar 13Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2026Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2026. Location: 2 floor no,12, chou tzu st., neihu district, taipei city Taiwan
New Risk • Jan 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 135% Dividend yield: 1.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Dividend is not well covered by cash flows (135% cash payout ratio). Share price has been volatile over the past 3 months (7.4% average weekly change).
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$87.60, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 26% over the past three years.
Valuation Update With 7 Day Price Move • Dec 10Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$100.00, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 8.5% over the past three years.
Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: NT$1.34 (vs NT$1.05 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.34 (up from NT$1.05 in 3Q 2024). Revenue: NT$489.5m (up 134% from 3Q 2024). Net income: NT$209.5m (up 43% from 3Q 2024). Profit margin: 43% (down from 70% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
공시 • Nov 05Handa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of TWD 1.232 billion.Handa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of TWD 1.232 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 11,200,000 Price(maximum): TWD 110
Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$139, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 153% over the past three years.
New Risk • Sep 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (44% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change).
Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 29%After last week's 29% share price gain to NT$106, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 94% over the past three years.
New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 44% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.
Upcoming Dividend • Jun 25Upcoming dividend of NT$1.51 per shareEligible shareholders must have bought the stock before 02 July 2025. Payment date: 25 July 2025. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.6%).
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to NT$60.20, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 18x in the Pharmaceuticals industry in Taiwan. Negligible returns to shareholders over past three years.
New Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Profit margins are more than 30% lower than last year (46% net profit margin).
공시 • Feb 20Handa Pharmaceuticals, Inc. announced that it expects to receive TWD 1.156 billion in funding from ScinoPharm Taiwan, Ltd.Handa Pharmaceuticals, Inc. announced a private placement of 17,000,000 shares at a price of TWD 68 per share for the gross proceeds of TWD 1,156,000,000 on February 18, 2025. The transaction will include participation from ScinoPharm Taiwan, Ltd. The transaction has been approved by investor's boards of directors.
공시 • Feb 19Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2025Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2025. Location: 2 floor no,1, sec.3 chung hsiao e. rd., da-an district, taipei city Taiwan
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improves as stock rises 19%After last week's 19% share price gain to NT$60.60, the stock trades at a trailing P/E ratio of 18.9x. Average forward P/E is 12x in the Pharmaceuticals industry in Taiwan. Negligible returns to shareholders over past three years.
New Risk • Dec 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Profit margins are more than 30% lower than last year (46% net profit margin).
New Risk • Oct 25New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Continuous dividend paying years: 1 Dividend yield: 1.7% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (8.6% average weekly change). Profit margins are more than 30% lower than last year (46% net profit margin).
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.73 (vs NT$1.90 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.73 (down from NT$1.90 in 2Q 2023). Revenue: NT$215.5m (down 24% from 2Q 2023). Net income: NT$102.4m (down 59% from 2Q 2023). Profit margin: 48% (down from 87% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$82.30, the stock trades at a trailing P/E ratio of 19.4x. Average forward P/E is 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 187% over the past three years.
Valuation Update With 7 Day Price Move • May 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$109, the stock trades at a trailing P/E ratio of 25.6x. Average forward P/E is 13x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 317% over the past three years.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.83 (vs NT$1.90 in 1Q 2023)First quarter 2024 results: EPS: NT$0.83 (down from NT$1.90 in 1Q 2023). Revenue: NT$217.4m (down 23% from 1Q 2023). Net income: NT$117.1m (down 53% from 1Q 2023). Profit margin: 54% (down from 87% in 1Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$141, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 465% over the past three years.
New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (8.4% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$144, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 415% over the past three years.
공시 • Apr 03Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024.
Reported Earnings • Apr 03Full year 2023 earnings released: EPS: NT$5.41 (vs NT$0.32 loss in FY 2022)Full year 2023 results: EPS: NT$5.41 (up from NT$0.32 loss in FY 2022). Revenue: NT$1.11b (up 460% from FY 2022). Net income: NT$726.9m (up NT$766.9m from FY 2022). Profit margin: 66% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 79% per year, which means it is significantly lagging earnings growth.
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (79% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (8.4% increase in shares outstanding).
Reported Earnings • Dec 28Third quarter 2023 earnings released: EPS: NT$1.07 (vs NT$0.18 in 3Q 2022)Third quarter 2023 results: EPS: NT$1.07 (up from NT$0.18 in 3Q 2022). Revenue: NT$240.0m (up 206% from 3Q 2022). Net income: NT$146.0m (up NT$122.8m from 3Q 2022). Profit margin: 61% (up from 30% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 70% p.a. on average during the next 2 years, compared to a 29% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 99% per year whereas the company’s share price has increased by 98% per year.
New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (120% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (8.3% increase in shares outstanding).
New Risk • Sep 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (120% accrual ratio). Minor Risk Shareholders have been diluted in the past year (7.9% increase in shares outstanding).
Reported Earnings • Apr 22Full year 2022 earnings released: NT$0.32 loss per share (vs NT$2.10 loss in FY 2021)Full year 2022 results: NT$0.32 loss per share (improved from NT$2.10 loss in FY 2021). Revenue: NT$197.7m (up NT$168.4m from FY 2021). Net loss: NT$40.0m (loss narrowed 84% from FY 2021). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 17First half 2022 earnings released: NT$0.71 loss per share (vs NT$1.01 loss in 1H 2021)First half 2022 results: NT$0.71 loss per share (up from NT$1.01 loss in 1H 2021). Revenue: NT$41.0m (up 198% from 1H 2021). Net loss: NT$86.4m (loss narrowed 26% from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 30Full year 2021 earnings released: NT$2.10 loss per share (vs NT$2.44 loss in FY 2020)Full year 2021 results: NT$2.10 loss per share (up from NT$2.44 loss in FY 2020). Net loss: NT$247.7m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 18First half 2021 earnings released: NT$1.01 loss per share (vs NT$1.26 loss in 1H 2020)First half 2021 results: Net loss: NT$116.6m (loss narrowed 20% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
공시 • Mar 20Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2021Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2021.
Is New 90 Day High Low • Feb 25New 90-day high: NT$30.70The company is up 15% from its price of NT$26.80 on 27 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period.
분석 기사 • Feb 24Handa Pharmaceuticals'(GTSM:6620) Share Price Is Down 26% Over The Past Three Years.Handa Pharmaceuticals, Inc. ( GTSM:6620 ) shareholders should be happy to see the share price up 12% in the last month...
Is New 90 Day High Low • Jan 04New 90-day high: NT$28.15The company is up 35% from its price of NT$20.90 on 07 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 12% over the same period.
분석 기사 • Dec 29We Think Handa Pharmaceuticals (GTSM:6620) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Is New 90 Day High Low • Nov 07New 90-day high: NT$27.15The company is up 1.0% from its price of NT$26.85 on 07 August 2020. The Taiwanese market is also up 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: NT$22.05The company is down 24% from its price of NT$29.15 on 23 June 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.